Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2016

View Archived Issues

Light-activated quantum dots show promise as phototherapy for multidrug-resistant infections

Oxeia Biopharmaceuticals develops OXE-103 for concussion

Lysyl oxidase identified as a factor in thrombosis risk

FDA approves Botox for the treatment of lower limb spasticity in adults

FDA clears IND application for Agenus' anti-CTLA-4 and anti-GITR antibodies

GSK discontinues development of alitretinoin in U.S.

Phase II results indicate sustained expression with AAT deficiency gene therapy

FDA grants orphan drug designation to TRACON's anti-endoglin antibody

Broad Institute Genomic Services and Takeda partner to expand genomic insight into Ninlaro

Genentech and Xenon Pharmaceuticals patent Nav1.7 channel blockers

Immunocore's IMCgp-100 gets FDA orphan drug designation for uveal melanoma

Incyte discloses KDM1A inhibitors

ST Pharm presents tankyrase-1 inhibitors

Pharmacyclics reports BTK inhibitors

Takeda's H. influenzae type b conjugate vaccine approved in Japan

Bonviva tablet approved in Japan for the treatment of osteoporosis

bioTheranostics to spin out from bioMerieux

Apollo Therapeutics Fund established to advance preclinical drug R&D at U.K. universities

Expanded FDA approvals for Opdivo + Yervoy and single-agent Opdivo in melanoma

Shire's acquisition of Dyax complete

Merck & Co. studies [11C]MK-6884 as PET imaging agent

FDA grants orphan drug designation to mutant KIT inhibitor for mastocytosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...